Fuhong Hanlin: Grants Alvogen Korea exclusive license for Hans.

robot
Abstract generation in progress

Jin10 Data reported on April 25 that Fuhong Hanlin announced that the company has entered into a licensing protocol with Alvogen Korea Co., Ltd., granting it exclusive rights to commercialize Hanshuang (Srilumab injection) in South Korea. Under the protocol, Alvogen Korea will pay an upfront payment of $5 million, with regulatory milestone payments not exceeding $9.5 million, commercial sales milestone payments not exceeding $97.5 million, and tiered royalties calculated based on annual net sales ranging from 18% to 25%. The licensing protocol will take effect from the date of signing and will initially last until the 10th anniversary of the first commercial sale of the licensed product.

View Original
The content is for reference only, not a solicitation or offer. No investment, tax, or legal advice provided. See Disclaimer for more risks disclosure.
  • Reward
  • Comment
  • Share
Comment
0/400
No comments